1 Min Read
Feb 7 (Reuters) - Revive Therapeutics Ltd
* Revive Therapeutics announces initiation of a Phase 2 study of revenue-004 (bucillamine) in cystinuria Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.